Bryan Roecklein
About Bryan Roecklein
Bryan A. Roecklein, Ph.D - Background
Bryan A. Roecklein, Ph.D, has an extensive background in corporate and commercial development within the pharmaceutical industry. His career began in scientific research as an independent investigator at the Fred Hutchinson Cancer Research Center from 1995 to 1998. He then transitioned into the business side of the pharmaceutical sector, leading commercial development projects at Kimeragen and ValiGene from 1998 to 2001. Over the years, Roecklein has accumulated a wealth of experience and knowledge in various roles within the industry.
Bryan A. Roecklein - Senior Vice President, Corporate Development
Bryan A. Roecklein serves as the Senior Vice President of Corporate Development, a role he has held since July 2015 after initially joining the company as Vice President of Corporate Development. In this capacity, Roecklein oversees critical aspects of corporate strategy and growth initiatives, leveraging his broad expertise to drive business development efforts.
Bryan A. Roecklein's Career at Meda Pharmaceuticals
Bryan A. Roecklein played a significant role at Meda Pharmaceuticals, where he was a part of the U.S. Executive Team, leading the Corporate Development function. During his tenure, he served as Vice President of Marketing and Business Development, managing responsibilities that encompassed Marketing, Access, Trade, and Acquisition Strategy. He joined MedPointe, later becoming Meda Pharmaceuticals, in 2001, holding various roles including Portfolio Management, New Product Planning, Marketing, Medical Education, and Commercial Development, until his departure in 2011.
Bryan A. Roecklein's Education and Expertise
Bryan A. Roecklein holds a Ph.D. in Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder, equipping him with a strong foundation in scientific research and technical knowledge. Additionally, he earned a Bachelor of Science degree from the University of Maryland, College Park. His educational background supports his extensive career in both the scientific and business spheres of the pharmaceutical industry.